Lakefront Biotherapeutics (LKFT) Non-Current Deferred Tax Liability (2014 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Non-Current Deferred Tax Liability for 5 consecutive years, with $20.3 million the latest figure, recorded in Q2 2025.

• Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $20.3 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $20.3 million (changed N/A YoY) and the FY2024 annual result came in at $23.5 million, down 12.48% from the prior year.
• Non-Current Deferred Tax Liability slipped to $20.3 million in Q2 2025 per LKFT's latest filing, from $21.3 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for LKFT reached as high as $28.8 million in Q3 2023 and fell as low as $20.3 million in Q2 2025.
• A 4-year average of $24.0 million and a median of $23.5 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability advanced 17.17% — and 2025, when it decreased 17.64%.
• Year by year, Non-Current Deferred Tax Liability stood at $22.9 million in 2022, then climbed by 17.17% to $26.9 million in 2023, then slipped by 12.48% to $23.5 million in 2024, then declined by 13.47% to $20.3 million in 2025.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $20.3 million, $21.3 million, and $23.5 million for Q2 2025, Q1 2025, and Q4 2024 respectively.